Education
About Us
Working with TipRanks
Follow Us
Infant Bacterial Therapeutics AB (DE:9IB)
FRANKFURT:9IB
Total Valuation
Infant Bacterial Therapeutics AB has a market cap or net worth of €71.03M. The enterprise value is €483.78M.
Market Cap€71.03M
Enterprise Value€483.78M
Share Statistics
Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,018,137
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Infant Bacterial Therapeutics AB’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is -82.17%.
Return on Equity (ROE)-0.80
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-82.17%
Return on Capital Employed (ROCE)-0.82
Revenue Per Employee500.00
Profits Per Employee-18.17M
Employee Count8
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Infant Bacterial Therapeutics AB is ―. Infant Bacterial Therapeutics AB’s PEG ratio is -2.50.
PE Ratio―
PS Ratio180517.03
PB Ratio4.24
Price to Fair Value4.24
Price to FCF-6.38
Price to Operating Cash Flow-8.04
PEG Ratio-2.50
Income Statement
In the last 12 months, Infant Bacterial Therapeutics AB had revenue of 4.00K and earned -136.91M in profits. Earnings per share was -10.16.
Revenue4.00K
Gross Profit4.00K
Operating Income-139.90M
Pretax Income-136.91M
Net Income-136.91M
EBITDA-136.91M
Earnings Per Share (EPS)-10.16
Cash Flow
In the last 12 months, operating cash flow was -102.84M and capital expenditures 0.00, giving a free cash flow of -102.84M billion.
Operating Cash Flow-102.84M
Free Cash Flow-102.84M
Free Cash Flow per Share-7.90
Dividends & Yields
Infant Bacterial Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.15
52-Week Price Change73.58%
50-Day Moving Average6.05
200-Day Moving Average4.81
Relative Strength Index (RSI)47.96
Average Volume (3m)0.00
Important Dates
Infant Bacterial Therapeutics AB upcoming earnings date is Nov 13, 2025, TBA (Confirmed).
Last Earnings DateAug 20, 2025
Next Earnings DateNov 13, 2025
Ex-Dividend Date―
Financial Position
Infant Bacterial Therapeutics AB as a current ratio of 3.33, with Debt / Equity ratio of 0.00%
Current Ratio3.33
Quick Ratio3.33
Debt to Market Cap0.00
Net Debt to EBITDA1.63
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Infant Bacterial Therapeutics AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Infant Bacterial Therapeutics AB EV to EBITDA ratio is -3.64, with an EV/FCF ratio of -4.41.
EV to Sales124.67K
EV to EBITDA-3.64
EV to Free Cash Flow-4.41
EV to Operating Cash Flow-4.41
Balance Sheet
Infant Bacterial Therapeutics AB has €176.32M in cash and marketable securities with €0.00 in debt, giving a net cash position of €176.32M billion.
Cash & Marketable Securities€176.32M
Total Debt€0.00
Net Cash€176.32M
Net Cash Per Share€13.54
Tangible Book Value Per Share€11.98
Margins
Gross margin is 100.00%, with operating margin of -3497550.00%, and net profit margin of -3422625.00%.
Gross Margin100.00%
Operating Margin-3497550.00%
Pretax Margin-3422625.00%
Net Profit Margin-3422625.00%
EBITDA Margin-3422625.00%
EBIT Margin-3422625.00%
Analyst Forecast
The average price target for Infant Bacterial Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―